KRON - Kronos Bio Inc
IEX Last Trade
1.05
0.059 5.619%
Share volume: 277,955
Last Updated: Fri 30 Aug 2024 09:59:52 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.99
0.06
5.95%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
7.15%
1 Month
-17.97%
3 Months
34.44%
6 Months
-14.63%
1 Year
-24.46%
2 Year
-74.14%
Key data
Stock price
$1.05
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.69 - $1.60
52 WEEK CHANGE
-$0.25
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO:
Region: US
Website: kronosbio.com
Employees: 99
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: kronosbio.com
Employees: 99
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
kronos bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, kronos utilizes its small molecule microarray (smm) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.
Recent news